Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking ...

As British research supplies and tools provider Abcam moves toward a potential multibillion-dollar sale, one of the company's founders and major shareholders is pushing back. Dr. Jonathan Milner, an ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Abcam has defended the handling of its proposed $5.7bn takeover by Danaher, insisting that the UK life sciences ...

Abcam PLC (NASDAQ:ABCM) is a $3.8 billion market cap biotechnology stock on the Nasdaq Global Select Market. It is moving its primary listing from Londons AIM (previously known as the Alternative ...

Life sciences company Abcam is one of Glassdoor's happiest places to work in the UK. The company is growing and hired around 500 people during the pandemic. One of its top recruiters offered five tips ...

For more than a decade, Abcam has been known as the “Amazon of Antibodies” because of its selection of over 110,000 products to research protein targets, from antibodies to proteins, lysates, ...

Horizon Discovery has rejected a £270 million ($367 million) takeover bid from Abcam. The gene editing specialist issued a strongly-worded rebuttal of the offer after Abcam went public with its plan, ...

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Abcam said today it will acquire AxioMx for up to $45 million, in a deal intended to enable the buyer to expand its offerings to customers working in infectious disease, toxins, nucleotides, and ...

Abcam to license in VHH phage library (1) from Twist, complementing in-house recombinant antibody capabilities Abcam to develop and commercialize antibodies for diagnostic and research use, with Twist ...

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today ...